Logo

ParAllele Secures $22.5 Million in Private Financing

Sep 23, 2003

NEW YORK, Sept. 23 (GenomeWeb News) - ParAllele BioScience said that it has raised $22.5 million in a round of Series B financing.

The round was led by a new investor, Mohr, Davidow Ventures, and included such existing investors as Abingworth Management, Index Ventures, and Versant Ventures.

Proceeds of the financing, said ParAllele, will be used to support the ongoing development and roll out of the company's SNP products.

Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.